Patents Examined by Elly-Gerald Stoica
  • Patent number: 11219668
    Abstract: The present invention is based upon the observation that inhibition of NPR-C Signaling pathway leads to the development of pulmonary arterial hypertension (PAH). Accordingly, the invention provides a mouse model for PAH, and proposes a method of using synthetic analogs of the NPR-C signaling pathway, specifically synthetic C-type atrial natriuretic factor or intermediates for, or modulators of, the NPR-C signaling pathway as anti-pulmonary vasculopathy agents. Activators of the NPR-C signaling pathway are disclosed to treat or prevent vasculopathy, including but not limited to PAH and other types of pulmonary hypertension, peripheral vascular disease, critical limb ischemia, coronary artery disease, and diabetic vasculopathy.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: January 11, 2022
    Inventor: Emmanuel Eroume A Egom
  • Patent number: 11208461
    Abstract: The present invention concerns the use of interleukin-8 (IL-8) as a biomarker for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: December 28, 2021
    Assignee: SANOFI
    Inventors: Marielle Chiron-Blondel, Diether Lambrechts, Emmanuelle Magherini, Vincent Thuillier
  • Patent number: 11203638
    Abstract: The present disclosure provides methods for the treatment of an allergic ocular disease (e.g., allergic conjunctivitis, keratoconjunctivitis, or giant papillary conjunctivitis). In particular, the present disclosure provides methods for the treatment of an allergic ocular disease through administration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of an allergic ocular disease.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: December 21, 2021
    Assignee: ALLAKOS INC.
    Inventors: Christopher Robert Bebbington, Bradford Andrew Youngblood, Nenad Tomasevic
  • Patent number: 11203636
    Abstract: The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: December 21, 2021
    Assignees: YALE UNIVERSITY, Novo Nordisk A/S
    Inventors: Jeffrey Testani, Veena Rao, Rahul Kakkar, Madhav N. Devalaraja, Chih-Hung Lo
  • Patent number: 11186648
    Abstract: The disclosure provides CD40-binding molecules comprising engineered human IgG domains, for example, human IgG1, IgG2, and IgG4 variants having mutations in the hinge domain, which exhibit altered binding activity to one or more Fc? receptors. Also described herein are methods for selectively activating or inhibiting immune responses in a subject using the CD40-binding molecules.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: November 30, 2021
    Inventors: Jieyi Wang, Yi Wu
  • Patent number: 11179463
    Abstract: The present invention relates to pharmaceutical formulations of a pharmaceutically active antigen binding protein, for example a monoclonal antibody. Such formulations comprise, in addition to the antigen binding protein, a buffering agent and a tonicity agent.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: November 23, 2021
    Inventors: Angela Blake-Haskins, Tristan Marshall, Melissa D. Perkins, Kristin O'Berry
  • Patent number: 11174311
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: November 16, 2021
    Inventors: Alastair David Griffiths Lawson, Daniel John Lightwood, Rebecca Jayne Munro, James Philip O'Connell, John Robert Porter
  • Patent number: 11168140
    Abstract: The present invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human interleukin-1 receptor accessory protein (hu-IL1RAP) and fully block the IL-1, IL-33, and IL-36 intracellular signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: November 9, 2021
    Assignee: 23andMe, Inc.
    Inventors: Davide Foletti, Erik Karrer, Germaine Fuh-Kelly, Kristie Ibarra, Quan Zheng, Yao-ming Huang, Lindsay Deis, Christine Wolak, Dominic Samuel Berns
  • Patent number: 11155597
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: October 26, 2021
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 11149072
    Abstract: The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: October 19, 2021
    Inventors: Frederick L. Locke, Dario Altieri, Scott Antonia, Claudio Anasetti, Dmitry Gabrilovich
  • Patent number: 11130801
    Abstract: A method of modulating growth factor responses of cells expressing C3a receptor (C3aR) and C5a receptor (C5aR) and at least one growth factor receptor includes administering to the cells at least one agent that modulates C3aR and/or C5aR signaling of the cells.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: September 28, 2021
    Inventors: M. Edward Medof, Michael G. Strainic, Elliot Pohlmann, Ming-Shih Hwang
  • Patent number: 11130802
    Abstract: Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGF?1 on cells but not to LAP-TGF?1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: September 28, 2021
    Assignees: Tilos Therapeutics, Inc., Merck Sharp & Dohme Corp.
    Inventors: Randall Burton, Jessie M. English, Barbara S. Fox, Stavros Kopsiaftis, Renee Moore, Patricia Rao, Kenneth J. Simon
  • Patent number: 11130805
    Abstract: Methods for reducing blood-brain barrier disruption in a subject treated with immunotherapy, the method comprising administering a recombinant GM-CSF antagonist to the subject. Methods for preserving blood-brain barrier integrity in a subject treated with immunotherapy, the method comprising administering a recombinant hGM-CSF antagonist to the subject. Methods for decreasing or preventing CAR-T cell therapy-induced neuroinflammation in a subject in need thereof, the method comprising administering a recombinant GM-CSF antagonist to the subject. Methods for preventing or reducing blood-brain barrier disruption in a subject treated with immunotherapy, the method comprising administering CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells) to the subject.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: September 28, 2021
    Assignee: HUMANIGEN, INC.
    Inventors: Cameron Durrant, Dale Chappell
  • Patent number: 11123404
    Abstract: The invention relates generally to compositions and methods for generating immunotolerant responses in a subject. Specifically, the invention relates to a composition comprising a sulfated polysaccharide and a bioactive polypeptide for generating an immunotolerant response.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: September 21, 2021
    Inventors: Smadar Cohen, Alon Monsonego
  • Patent number: 11103555
    Abstract: Cancer is a complex group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. Described herein are compositions and methods for the treatment of cancer.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: August 31, 2021
    Inventors: Raymond Wong, Robert Cameron
  • Patent number: 11098110
    Abstract: A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: August 24, 2021
    Assignee: NOVARTIS AG
    Inventors: Margarita Gekkieva, Peter Sallstig, Werner Schmidt, James Warburton, Andreas Weichselberger
  • Patent number: 11096989
    Abstract: The present invention provides a method of treating cancer with a combination of IL-2 and an integrin-binding-Fc fusion protein. The methods of the invention can be applied to a broad range of cancer types.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: August 24, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Dane Wittrup, Jennifer R. Cochran, Byron Hua Kwan
  • Patent number: 11098114
    Abstract: The present invention is directed to an antibody composition for oral administration comprising intact blood-derived polyclonal antibodies that bind to a human tumour necrosis factor ? (TNF?), and means for protecting the antibodies during gastrointestinal transit, as well as methods for manufacturing, kits, and therapeutic uses of the same.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: August 24, 2021
    Inventors: John Landon, Ruth Elizabeth Coxon
  • Patent number: 11091555
    Abstract: This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: August 17, 2021
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Helen L. Collins, James Hnatyszyn, Hong Xiang, Xiang Zhang
  • Patent number: 11078264
    Abstract: A method of treating a pregnant female subject includes administering to the pregnant female subject an effective amount of a Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) inhibitor, wherein the effective amount of the GM-CSF inhibitor is effective to reduce, prevent or delay preterm birth.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: August 3, 2021
    Inventors: Christopher Nold, Anthony Vella